Full-Time

Director Employee Relations and Workplace Effectiveness

Posted on 9/4/2026

Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

51-200 employees

Biopharmaceutical company developing neurodegenerative therapies

Compensation Overview

$197k - $222k/yr

Cambridge, MA, USA

Hybrid

Remote within the United States, with several annual visits to Cambridge, Massachusetts. Preference is given to New England residents.

Bachelor's

Category
People & HR (1)
Required Skills
Data Analysis

Get referred to Amylyx Pharmaceuticals

See people who can refer or advise you

Requirements
  • A bachelor's degree and 10+ years of progressive Human Resources experience supporting employee relations, investigations, and performance management; equivalent relevant professional experience will also be considered in lieu of education requirements.
  • Demonstrated experience independently conducting and documenting complex workplace investigations.
  • Ability to travel as needed to conduct investigations.
  • Strong working knowledge of United States employment laws and human resources and employee-relations best practices.
  • Experience partnering with Human Resources Business Partners and advising managers and leaders on complex employee situations.
  • Strong judgment and ability to appropriately assess employee-relations risk and determine when matters should be escalated.
  • Strong interpersonal, written, and verbal communication skills, including the ability to navigate sensitive and difficult situations with professionalism and discretion.
  • Strong organizational and documentation skills with the ability to manage multiple employee matters simultaneously.
  • Ability to operate in an environment where responsibilities may evolve as the organization grows.
  • Ability to work remotely from a setting meeting privacy, reliable internet, telephone, and video-conferencing requirements.
Responsibilities
  • Serve as a subject-matter expert for employee-relations matters, partnering with Human Resources Business Partners on complex or sensitive employee situations.
  • Lead or support workplace investigations involving employee complaints, conduct concerns, discrimination, harassment, retaliation, workplace behavior, and other policy matters.
  • Conduct objective, thorough, and timely investigations, including interviews, documentation review, findings, and recommendations.
  • Provide guidance regarding corrective action, performance concerns, conflict resolution, and employment decisions.
  • Ensure appropriate documentation and consistency in handling employee-relations matters.
  • Partner with Legal and Human Resources leadership on matters presenting heightened employment, compliance, or organizational risk.
  • Provide managers and Human Resources Business Partners with practical guidance on performance management, accountability, communication, conflict resolution, and difficult employee conversations.
  • Support the development and review of performance-improvement plans, written warnings, corrective actions, and other performance documentation.
  • Help managers distinguish between performance, conduct, capability, and workplace-relationship issues and determine appropriate interventions.
  • Build manager capability so routine employee matters can be addressed at the manager and Human Resources Business Partner level while higher-risk situations are appropriately escalated.
  • Partner with Human Resources Business Partners and Human Resources leadership to identify opportunities to strengthen team effectiveness, employee engagement, communication, and retention.
  • Identify recurring workplace themes and organizational pain points and recommend proactive solutions.
  • Support interventions for teams experiencing conflict, leadership challenges, communication breakdowns, or other workplace-effectiveness concerns.
  • Partner across Human Resources on initiatives designed to strengthen manager effectiveness and the overall employee experience.
  • Help ensure employment practices are consistent with applicable federal, state, and local employment laws and company policies.
  • Maintain and enhance employee-relations policies, guidelines, templates, and manager resources.
  • Partner with Legal on policy development and employment-related risk mitigation.
  • Support consistent application and interpretation of Human Resources policies across the organization.
  • Remain current on evolving employment practices and regulatory requirements and translate changes into practical guidance for Human Resources and managers.
  • Partner with Learning and Organizational Development to develop and deliver training and resources for managers and employees on performance management, respectful workplace practices, effective feedback, conflict resolution, investigations, and employee-relations fundamentals.
  • Identify training needs based on employee-relations trends and recurring manager challenges.
  • Partner with Human Resources colleagues to incorporate employee-relations learnings into broader manager and leadership-development programs.
  • Establish meaningful tracking and reporting of employee-relations matters, including case types, outcomes, recurring themes, and organizational trends.
  • Analyze employee feedback, turnover, exit-interview information, employee-relations cases, and other workforce data to identify emerging risks or opportunities.
  • Provide Human Resources leadership and Human Resources Business Partners with actionable insights and recommendations.
  • Use trends and case learnings to inform policies, manager education, organizational interventions, and broader people strategies.
Desired Qualifications
  • Strong working knowledge of United States employment laws and Human Resources and employee-relations best practices, with experience supporting employees across multiple states.
  • Experience in a growing, changing, or highly regulated organization.
  • Biotechnology, pharmaceutical, or life sciences experience.
Amylyx Pharmaceuticals

Amylyx Pharmaceuticals

View

Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, with a focus on ALS and Alzheimer's disease. Its main asset is AMX0035, currently in clinical trials, including the CENTAUR study for ALS and the PEGASUS study for late mild cognitive impairment or early dementia due to Alzheimer’s disease. The company advances products through rigorous, randomized, double-blind, placebo-controlled trials to demonstrate safety and efficacy before pursuing commercialization. In addition to research, Amylyx engages in awareness and community campaigns to support patients, caregivers, and researchers. The company aims to bring validated therapies to market to improve patient outcomes and generate revenue by selling treatments to healthcare providers and patients.

Company Size

51-200

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

2013

Get referred to Amylyx Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • LUCIDITY met its primary endpoint on August 18, 2026, cutting events 55%.
  • Amylyx priced a $500.2 million offering on August 19, 2026, funding commercialization.
  • The company opened expanded access on May 5, 2026, building physician and patient awareness.

What critics are saying

  • Amylyx depends on one 78-patient avexitide filing; FDA rejection kills 2027 revenue.
  • The August 2026 offering dilutes holders and signals expensive launch readiness spending.
  • After Relyvrio’s 2024 withdrawal, another failure would leave Amylyx without approved products.

What makes Amylyx Pharmaceuticals unique

  • Avexitide is the first GLP-1 receptor antagonist for post-bariatric hypoglycemia.
  • FDA Breakthrough Therapy status and Orphan designations shorten Amylyx’s regulatory path.
  • Amylyx pairs rare-disease endocrinology with ongoing ALS and Wolfram syndrome programs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-12%
Yahoo Finance
Aug 27th, 2026
Oracle and 2 high-growth stocks backed by rising eurozone credit demand

Eurozone private sector credit growth is accelerating as households and businesses show greater confidence in borrowing. This environment supports companies with strong balance sheets and earnings growth potential. Oracle, the global enterprise software firm, benefits from this trend through its cloud business. The company generates roughly US$67.4 billion in revenue, with about US$58.5 billion from cloud and software services. Its Oracle Cloud SaaS suite and infrastructure drive recurring subscription revenue through products like Fusion Cloud ERP and NetSuite. Oracle carries a market capitalisation of approximately US$417 billion. The rising credit demand backdrop favours established technology companies like Oracle that can help businesses invest in digital transformation and operational systems when borrowing conditions improve.

wallstreet:online AG
Aug 20th, 2026
Amylyx Pharmaceuticals announces pricing of an upsized $500 million underwritten public offering of common stock.

Amylyx Pharmaceuticals announces pricing of an upsized $500 million underwritten public offering of common stock. Foto: adobe.stock.com Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public offering price of $35.50 per share. In addition, Amylyx has granted the underwriters a 30-day option to purchase up to an additional 2,113,500 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the shares of common stock are being offered by Amylyx. The gross proceeds to Amylyx from this offering are expected to be $500.2 million, before deducting underwriting discounts and commissions and offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. Amylyx intends to use the net proceeds from this offering, together with existing cash, cash equivalents and marketable securities, for: * Pre-commercial activities for avexitide, including securing additional manufacturing capacity; * Research and development; and * Working capital and other general corporate purposes. The offering is expected to close on or about August 21, 2026, subject to the satisfaction of customary closing conditions. Leerink Partners, Morgan Stanley, Guggenheim Securities and LifeSci Capital are acting as joint bookrunning managers for the offering. The shares described above are being offered pursuant to a shelf registration statement on Form S-3ASR (File No. 333-293956) that became automatically effective upon filing with the Securities and Exchange Commission (the "SEC") on March 3, 2026. This offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC on August 18, 2026, and are available on the SEC's website located at www.sec.gov. A final prospectus supplement containing additional information relating to the offering and accompanying prospectus will be filed with the SEC and will be available on the SEC's website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to this offering may also be obtained by contacting: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at [email protected]; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, telephone: (212) 518-9544, email: [email protected]; and LifeSci Capital LLC, Attention: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at [email protected]. Business Wire (engl.) Autor folgen Verfasst von Letzte Änderung20.08.2026, 05:06 Im Artikel enthaltene Werte

Business Wire
Aug 19th, 2026
Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of $350.0 milli...

Gate.com
Aug 18th, 2026
AMLX stocks surge 64% on positive avexitide trial data, launches $350M offering.

AMLX stocks surge 64% on positive avexitide trial data, launches $350M offering. 2026-08-18 14:39:33 Key takeaways. * Amylyx Pharmaceuticals announced positive LUCIDITY trial data for avexitide and launched a $350 million public offering on Tuesday. * The late-stage trial demonstrated a 55% reduction in serious hypoglycemia events with a clean safety profile in 78 patients. * Amylyx plans to file for U.S. FDA approval by end of 2026 and aims for a 2027 market launch if approved. Amylyx Pharmaceuticals (AMLX) launched a $350 million underwritten public offering of common shares after hours on Tuesday, following the announcement of positive topline data from its late-stage LUCIDITY trial of avexitide for post-bariatric hypoglycemia. The stock closed 64% higher on Tuesday, marking its best single-day performance, and edged up 2% after hours. The capital raise will fund pre-commercial work for avexitide, including additional manufacturing capacity, research and development, and general corporate needs. Post-bariatric hypoglycemia is a rare condition causing repeated dangerous drops in blood sugar after weight-loss surgery. Amylyx has no FDA-approved therapies as of August, after its previously approved product Relyvrio was withdrawn from the market following a failed late-stage trial in 2024. LUCIDITY trial shows 55% reduction in serious hypoglycemia events. The late-stage LUCIDITY study evaluated avexitide, a once-daily injection, in 78 patients with post-bariatric hypoglycemia. Avexitide reduced the rate of serious low-blood-sugar events by 55% compared with placebo. The trial met every secondary endpoint with clear, meaningful reductions and demonstrated a clean safety profile. Amylyx plans to file for U.S. approval by the end of 2026 and aims for a 2027 launch if approved. Amylyx launches $350M public offering to fund avexitide commercialization. Amylyx announced the underwritten public offering after hours on Tuesday. Proceeds from the offering, combined with existing cash, will support pre-commercial activities for avexitide, including expansion of manufacturing capacity, research and development efforts, and general corporate purposes. The offering is subject to market conditions. The capital raise positions the company to transition from clinical success toward potential commercialization following the positive LUCIDITY trial results. Analysts raise price targets following trial data. H.C. Wainwright raised its price target on Amylyx to $55 from $34 and maintained a Buy rating. The firm stated that the LUCIDITY results substantially de-risk avexitide, citing the 55% reduction in events, strong secondary outcomes, clean safety profile, and a planned year-end filing that supports a 2027 launch and approximately $1.3 billion in risk-adjusted peak U.S. sales. Stifel lifted its price target to $45 from $21 and kept a Buy rating. The firm described the data as a "best-case scenario" and "clear win" on the primary endpoint with clean safety, stating the results substantially de-risk approval and shift focus to commercial execution in a market estimated at $2 billion. Citi described avexitide's profile as "highly differentiated" and said the company now has a "persuasive foundation" for FDA approval. Citi maintained a Buy rating with a $32 price target. Retail sentiment shifts to extremely bullish on Stocktwits. On Stocktwits, retail sentiment around AMLX stock rose from neutral to extremely bullish territory over the past 24 hours, while message volume increased from normal to extremely high levels. One Stocktwits user expressed hopes for a further rally up to $40 per share. Another user commented that dilution risk is now offset after the stock offering. AMLX stock has gained approximately 200% year-to-date. Faq. What were the results of Amylyx's LUCIDITY trial for avexitide? The late-stage LUCIDITY trial in 78 patients showed that avexitide reduced the rate of serious low-blood-sugar events by 55% compared with placebo. The trial met all secondary endpoints with meaningful reductions and demonstrated a clean safety profile. When does Amylyx plan to file for FDA approval of avexitide? Amylyx plans to file for U.S. approval by the end of 2026 and aims for a 2027 launch if approved. How much capital did Amylyx raise in its public offering? Amylyx launched an underwritten public offering of $350 million in common shares after hours on Tuesday. The proceeds will fund pre-commercial work for avexitide, including manufacturing capacity expansion, research and development, and general corporate needs. Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.

MarketScreener
Aug 18th, 2026
Amylyx Pharmaceuticals launches $350M public offering for avexitide pre-commercial activities

Amylyx Pharmaceuticals has launched an underwritten public offering of $350 million in common stock. The company also plans to grant underwriters a 30-day option to purchase up to an additional $52.5 million worth of shares. Amylyx intends to use the net proceeds, along with existing cash and securities, for pre-commercial activities for avexitide, including securing additional manufacturing capacity, research and development, and general corporate purposes. Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital are serving as joint bookrunning managers for the offering. The shares are being offered under a shelf registration statement filed with the Securities and Exchange Commission on 3 March 2026. The offering is subject to market conditions, with no assurance regarding completion or final terms.